Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
| Market Cap | 2.72B +41.5% |
| Revenue (ttm) | 1.04B +4.5% |
| Net Income | 122.77M -11.9% |
| EPS | 1.72 -9.1% |
| Shares Out | n/a |
| PE Ratio | 22.12 |
| Forward PE | n/a |
| Dividend | 0.41 (1.41%) |
| Ex-Dividend Date | Aug 28, 2025 |
| Volume | 100 |
| Open | 29.00 |
| Previous Close | 28.94 |
| Day's Range | 29.00 - 29.00 |
| 52-Week Range | 27.52 - 32.30 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 13, 2026 |
About HTSUF
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asi... [Read more]
Financial Performance
In fiscal year 2026, HTSUF's revenue was 163.02 billion, an increase of 4.50% compared to the previous year's 156.01 billion. Earnings were 19.16 billion, a decrease of -11.94%.
Financial numbers in JPY Financial StatementsNews
Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO
Japan's Hisamitsu Pharmaceutical is planning to take the company private in a management buyout for nearly 400 billion yen ($2.55 billion), it said in a filing late on Tuesday.